Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate
Chronic myeloid leukemia (CML) is characterized by the presence of a constitutively active Abl kinase, which is the product of a chimeric BCR-ABL gene, caused by the genetic translocation known as the Philadelphia chromosome. Imatinib, a selective inhibitor of the Bcr-Abl tyrosine kinase, has significantly improved the clinical outcome of patients with CML. However, subsets of patients lose their response to treatment through the emergence of imatinib-resistant cells, and imatinib treatment is less durable for patients with late stage CML. Although alternative Bcr-Abl tyrosine kinase inhibitors have been developed to overcome drug resistance, a cocktail therapy of different kinase inhibitors and additional chemotherapeutics may be needed for complete remission of CML in some cases. Chlorambucil has been used for treatment of B cell chronic lymphocytic leukemia, non-Hodgkin's and Hodgkin's disease. Here we report that a DNA sequence-specific pyrrole-imidazole polyamide-chlorambucil conjugate, 1R-Chl, causes growth arrest of cells harboring both unmutated BCR-ABL and three imatinib resistant strains. 1R-Chl also displays selective toxicities against activated lymphocytes and a high dose tolerance in a murine model. © 2008 Chou et al.
Chou, C. James; O'Hare, Thomas; Lefebvre, Sophie; Alvarez, David; Tyner, Jeffrey W.; Eide, Christopher A.; Druker, Brian J.; and Gottesfeld, Joel M., "Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate" (2008). Kean Publications. 2456.